



*"Investing wisely in
healthcare innovation
for the benefit of society
and our members"*



August 2016

Members: 165

Countries: 13

Investments: 3

Save the Date: Sep. 26

MedPro's meet-and-greet event to take place next month in NYC

There's a party on the calendar and you're invited. As was detailed in an email distributed last week, MedPro is hosting a social gathering that is open to Members and their guests, especially other doctors, and prospective members. It will offer an opportunity to talk with MedPro management and your fellow Members about developments in healthcare, MedPro's focus, results achieved to date and plans for the future. Thank you to those who have responded so far. We expect to be in communication about the party once more as the date nears. Current information on the occasion is as follows:

Light refreshments will be served.

Date: Monday, September 26th

Time: 6:00-8:00 pm EDT

Location: Eaton & Van Winkle, LLP, 3 Park Avenue, New York, NY 10016 (16th floor)

Dress Code: none

Other Info: please bring ID to check in at the front desk and tell the security guard you are visiting the Eaton & Van Winkle office

We are sincerely looking forward to meeting as many of you as can make it.

Impleo: Closing the Investment Round

MedPro's third investment soon to be finalized

A first closing for Impleo was slated for Monday, August 15th. By this point, you are likely well aware of the investment opportunity, but if you'd like to refresh your memory, feel free to visit the News page of our recently revamped website (<http://www.medproinvestors.com/news>). In the MedPro Newsletters section, you will find a thorough summary of our rationale to invest included as the lead story of our May 2016 issue. Our specialist, a noted gastroenterologist, confirmed that Impleo's bulking agent – which had already succeeded in an earlier clinical trial, was already FDA approved for another indication, and is inserted by a gastroenterologist with an endoscope at the base of the esophagus – offered a promising cure for reflux.

For any wishing to participate beyond this first closing, minimum investment is \$25,000 and checks should be made payable to "MedPro Investors – Impleo LLC". Please submit the completed [Investment Agreement](#) with your check as well. It should be noted that while those who decide to invest from this point forward can expect the same positive return upon exit, it is uncertain that they will receive the added bonus of the 25% investor rebate, which was approved by the State of Minnesota for the group of investors that has already committed. The state's budget for this credit has been exhausted, though there remains the possibility that more state funds for this purpose may become available.

Portfolio Company Updates

The latest on Immunomic Therapeutics and B-Temia

Immunomic Therapeutics

Immunomic continues to make strides in advancing its LAMP-Vax technology. While still advancing allergy vaccines in conjunction with Astellas Pharma, Immunomic has also entered the immuno-oncology space, where it has conducted an early clinical trial in glioblastoma (now entering a phase 2 trial), AML and metastatic melanoma. Note that those who invested in the

company in late 2014 already received a special dividend payment equal to over 3x their initial investment just after one year.

B-Temia

B-Temia is currently making progress towards a U.S. clinical trial. Earlier this summer, the company received a \$300,000 grant from the City of Quebec which will be used to advance the Dermoskeleton technology as part of a collaboration with the city's police and fire departments.

Around the Corner

Looking ahead to our next financing

Once Impleo closes, there is a pipeline of investment opportunities currently under consideration. Here is a glance at some of the target indications and therapeutic approaches across these companies:

Immuno-Oncology

As has been previously reported, MedPro has licensed technology from a major medical research institution into a NewCo targeting HER2 positive prostate, breast and other cancers. Early clinical results have shown strong patient responses to the vaccine. The institutional source of the technology will continue to support the NewCo in future trials and complement external funding. MedPro placed a CEO with expert knowledge to team with the scientists, conducted a competitive landscape analysis and confirmed that the planned combination therapy with two compatible checkpoint blockers will be the only one of its kind. The startup is ready to move forward by making some key hires and is seeking MedPro financing starting later this month.

A Protective Device for Cell Delivery

A company that remains on our radar has developed an implantable cell pouch which houses and protects therapeutic cells. The primary target is the treatment of diabetes. There has been clinical proof of concept demonstrated in patients who have received allogenic islet cells harvested from cadavers. The pouch has become well vascularized, enabling the islets to produce insulin in response to changes in blood glucose levels. The Company also plans to use the pouch to house stem cells and other cells which have been epigenetically engineered to produce insulin. We are waiting until FDA approval of the clinical protocol is complete before engaging further. This is expected by the end of the summer.

Infectious Disease

Antibiotic resistance represents a severe threat and over the years there has been a decline in the resources devoted to this problem. As such, we have explored the merits of one company's small molecule drugs initially targeting antibiotic resistant tuberculosis. Our specialist's opinion was affirmative.

Liver Disease

Another company that we have been monitoring seeks to treat patients with liver diseases using allogeneic progenitor cells harvested from healthy adult liver tissue. The cells are injected through the company's product.

Others

It should be noted that the above opportunities only represent a subset of potential future investments. Our interests and capacity to evaluate opportunities in many fields of medical specialization, thanks to our specialist Members, is truly extensive. We welcome suggestions of financing opportunities from MedPro Members and friends. We seek companies with some demonstration of clinical efficacy which show promise of advancing the standard of care. Companies may be public or private.

MedGrow

Help us increase the size of our Membership

MedPro Investors LLC has grown to 165 healthcare professional Members. We expect to continue to substantially increase that number. Your connections and ability to help in this effort are extremely valuable. The larger we are, the more areas of expertise we can cover and the more we will be able to make significant investments in promising opportunities. The best sources of new Members are current MedPro Members. For this reason, we encourage you to recommend other healthcare professionals to join our ranks. Please do not hesitate to send us the names of any healthcare professional friends, colleagues or associates that come to mind. A simple list including names and email addresses can be sent to steve@medproinvestors.com.



Visit Us:

<http://www.medproinvestors.com/>

Email Us:

isaac@medproinvestors.com

Call Us:

1-212-561-3611 (Steve)

Copyright © 2016 MedPro Investors LLC, All rights reserved.

[unsubscribe from this list](#) [update subscription preferences](#)
